These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 29204893)

  • 41. Development of a novel PRO instrument for use in familial chylomicronemia syndrome.
    Davidson D; Slota C; Vera-Llonch M; Brown TM; Hsieh A; Fehnel S
    J Patient Rep Outcomes; 2021 Aug; 5(1):72. PubMed ID: 34382114
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The patient-reported impact of scars measure: development and validation.
    Brown BC; McKenna SP; Solomon M; Wilburn J; McGrouther DA; Bayat A
    Plast Reconstr Surg; 2010 May; 125(5):1439-1449. PubMed ID: 20440163
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Qualitative Assessment of the Symptoms and Impact of Pancreatic Exocrine Insufficiency (PEI) to Inform the Development of a Patient-Reported Outcome (PRO) Instrument.
    Johnson CD; Arbuckle R; Bonner N; Connett G; Dominguez-Munoz E; Levy P; Staab D; Williamson N; Lerch MM
    Patient; 2017 Oct; 10(5):615-628. PubMed ID: 28332032
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of a New Tool for Evaluating the Benefit of Preventive Treatments for Migraine on Functional Outcomes - The Migraine Functional Impact Questionnaire (MFIQ).
    Hareendran A; Skalicky A; Mannix S; Lavoie S; Desai P; Bayliss M; Thach AV; Mikol DD; Buse DC
    Headache; 2018 Nov; 58(10):1612-1628. PubMed ID: 30374958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity.
    Askanase AD; Daly RP; Okado M; Neville K; Pong A; Hanrahan LM; Merrill JT
    Health Qual Life Outcomes; 2019 Jun; 17(1):99. PubMed ID: 31174541
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Content validity of a novel patient-reported and observer-reported outcomes assessment to evaluate ocular symptoms associated with infectious conjunctivitis in both adult and pediatric populations.
    Sarda SP; De La Cruz M; Flood EM; Vanya M; Hwang DG; Ta CN; Narvekar A
    Health Qual Life Outcomes; 2019 Oct; 17(1):163. PubMed ID: 31666074
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J).
    Okubo Y; Mabuchi T; Iwatsuki K; Elmaraghy H; Torisu-Itakura H; Morisaki Y; Nakajo K
    J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):325-332. PubMed ID: 30317671
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Validation of psychometric properties and development of response criteria for the psoriasis symptoms and signs diary (PSSD): results from a phase 3 clinical trial.
    Armstrong A; Puig L; Langley R; Tsai TF; Song M; Wasfi Y; Jiang J; Li S; Han C
    J Dermatolog Treat; 2019 Feb; 30(1):27-34. PubMed ID: 28797188
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials.
    McKenna SP; Cook SA; Whalley D; Doward LC; Richards HL; Griffiths CE; Van Assche D
    Br J Dermatol; 2003 Aug; 149(2):323-31. PubMed ID: 12932239
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report.
    Coons SJ; Gwaltney CJ; Hays RD; Lundy JJ; Sloan JA; Revicki DA; Lenderking WR; Cella D; Basch E;
    Value Health; 2009 Jun; 12(4):419-29. PubMed ID: 19900250
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Modular Health-Related Quality of Life Instrument for Electronic Assessment and Treatment Monitoring: Web-Based Development and Psychometric Validation of Core Thrive Items.
    Wicks P; McCaffrey S; Goodwin K; Black R; Hoole M; Heywood J
    J Med Internet Res; 2019 Jan; 21(1):e12075. PubMed ID: 30681962
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessing the Patient Experience of Hypoparathyroidism Symptoms: Development of the Hypoparathyroidism Patient Experience Scale-Symptom (HPES-Symptom).
    Brod M; Waldman LT; Smith A; Karpf D
    Patient; 2020 Apr; 13(2):151-162. PubMed ID: 31552607
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Validation of the QFS measuring the frequency and satisfaction in social behaviours in psychiatric adult population].
    Zanello A; Weber Rouget B; Gex-Fabry M; Maercker A; Guimon J
    Encephale; 2006; 32(1 Pt 1):45-59. PubMed ID: 16633290
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and content validation of two new patient-reported outcome measures for endometriosis: the Endometriosis Symptom Diary (ESD) and Endometriosis Impact Scale (EIS).
    Gater A; Taylor F; Seitz C; Gerlinger C; Wichmann K; Haberland C
    J Patient Rep Outcomes; 2020 Feb; 4(1):13. PubMed ID: 32072316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Patient experiences with oily skin: the qualitative development of content for two new patient reported outcome questionnaires.
    Arbuckle R; Atkinson MJ; Clark M; Abetz L; Lohs J; Kuhagen I; Harness J; Draelos Z; Thiboutot D; Blume-Peytavi U; Copley-Merriman K
    Health Qual Life Outcomes; 2008 Oct; 6():80. PubMed ID: 18925946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and psychometric evaluation of the self-assessment of psoriasis symptoms (SAPS) - clinical trial and the SAPS - real world patient-reported outcomes.
    Armstrong AW; Banderas B; Foley C; Stokes J; Sundaram M; Shields AL
    J Dermatolog Treat; 2017 Sep; 28(6):505-514. PubMed ID: 28147886
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Hyperhidrosis Disease Severity Measure-Axillary: Conceptualization and Development of Item Content.
    Kirsch BM; Burke L; Hobart J; Angulo D; Walker PS
    J Drugs Dermatol; 2018 Jul; 17(7):707-714. PubMed ID: 30005091
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Cystic Fibrosis Impact Questionnaire: qualitative development and cognitive evaluation of a new patient-reported outcome instrument to assess the life impacts of cystic fibrosis.
    McCarrier KP; Hassan M; Hodgkins P; Suthoff E; McGarry LJ; Martin ML
    J Patient Rep Outcomes; 2020 May; 4(1):36. PubMed ID: 32405878
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Qualitative assessment of the content validity of the Dermatology Life Quality Index in patients with moderate to severe psoriasis.
    Safikhani S; Sundaram M; Bao Y; Mulani P; Revicki DA
    J Dermatolog Treat; 2013 Feb; 24(1):50-9. PubMed ID: 22007701
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development and content validity of a hemodialysis symptom patient-reported outcome measure.
    Flythe JE; Dorough A; Narendra JH; Wingard RL; Dalrymple LS; DeWalt DA
    Qual Life Res; 2019 Jan; 28(1):253-265. PubMed ID: 30229532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.